Roscovitine

DESCRIPTION

Roscovitine is a potent inhibitor of CDK2/E, CDk2/A, CDk5, CDk7, and CDk9, which are key regulators of cell cycle progression. It stimulates apoptosis in cancer cells and is reported to prevent embryonic development.

DETAILS

Purity: ≥98%
Synonyms: Seliciclib, R-roscovitine, CYC-202
Cas Number: 186692-46-6
References: Bach, S., Knockaert, M., Reinhardt, J., Lozach, O., Schmitt, S., Baratte, B., ... & Liang, D. C. (2005). Roscovitine targets, protein kinases and pyridoxal kinase. Journal of Biological Chemistry, 280(35), 31208-31219. De Azevedo, W. F., Leclerc, S., Meijer, L., Havlicek, L., Strnad, M., & Kim, S. H. (1997). Inhibition of cyclin‐dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. European journal of biochemistry, 243(1‐2), 518-526. Meijer, L., Borgne, A., Mulner, O., Chong, J. P., Blow, J. J., Inagaki, N., ... & Moulinoux, J. P. (1997). Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin‐dependent kinases cdc2, cdk2 and cdk5. European journal of biochemistry, 243(1‐2), 527-536.
Application: FA
Formulation: Crystalline solid
Chemical Name: (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol
Molecular Weight: 354.5
Molecular Formula: C19H26N6O
Storage Conditions: Product should be kept at -20°C.
Pubchem Openeye Can Smiles: CCC(CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=CC=C3